Gabriel de Alba

Sonar Entertainment, Inc. develops, produces, finances and distributes premium content for global audiences. It offers a platform for creative talent with the support of a full-service studio and global distribution company. The company provides new long-form television content, including domestic made-for-television, movies and mini-series. Sonar Entertainment was founded on August 24, 2007 and is headquartered in New York, US.

Cirque du Soleil, Inc. operates as a theatrical entertainment company. The firm creates and produces shows, events, and special projects; and provides creative content for various projects. The company was founded by Guy Lalibert? in 1984 and is headquartered in Montreal, Canada.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Gateway Casinos & Entertainment Ltd. engages in the operation and management of casinos. The company was founded in 1992 and is headquartered in Burnaby, Canada.

The Catalyst Capital Group Inc (catalyst capital group) is private equity firm founded in 2002 by Jeremy Keele, Patrick McKenna, James Lee Sorenson. The firm is headquartered in Ontario, Canada.

Evolve Biologics, Inc. is a Canadian plasma-derived therapeutics company headquartered in Mississauga, CA. The company is focused on commercializing a portfolio of product candidates, including intravenous immunoglobulin (IVIG) and human serum albumin (HSA), both of which are in advanced stages of regulatory approval with the FDA and Health Canada. Evolve's state-of-the-art facility is the first to use its innovative and proprietary technology, Plasmacap EBA®, to commercially produce plasma-derived therapeutics. The company has recently appointed James V. Caggiano as CEO, who brings nearly 30 years of experience in the biotech, pharma, and medical device industries.